Consistently, Žáčková et al. demonstrated that lower serum levels of Hsp90α in patients with chronic myeloid leukemia were correlated with good response to therapy [17]. The gene discussed is HSP90AA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.